Spark Therapeutics publicly listed in 2015 and is set to net Children's Hospital of Philadelphia up to $458m following its acquisition by Roche.

Spark Therapeutics, a US-listed gene therapy developer originally spun out from Children’s Hospital of Philadelphia (CHOP), is to be acquired by pharmaceuticals supplier Roche for $114.50 per share, Reuters reported yesterday. The transaction is anticipated to total $4.3bn when it closes in the second quarter of 2019, generating Spark more than twice its closing price…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.